New York, Jan 27, 2026, 14:43 ET — Regular session
- Shares of BSX held steady in afternoon trading following Boston Scientific’s announcement that it finalized its acquisition of Nalu Medical
- Boston Scientific’s pain-management portfolio now includes a peripheral nerve stimulation platform thanks to the deal
- Investors are now eyeing the Feb. 4 results release and call
Shares of Boston Scientific Corporation held steady Tuesday following the completion of its acquisition of Nalu Medical. By 2:43 p.m. ET, the stock dipped just 0.01%, trading at $93.54.
The company revealed the deal back in October, paying about $533 million upfront for the equity it didn’t yet own. That puts the total transaction value at roughly $600 million. Nalu develops a peripheral nerve stimulation system—therapy that sends small electrical pulses to block pain signals. Boston Scientific expects Nalu to bring in over $60 million in sales for 2025, with growth exceeding 25% in 2026. “Peripheral nerve stimulation is an exciting field with a significant unmet patient need,” said Jim Cassidy, president of Neuromodulation at Boston Scientific. Boston Scientific
The timing is key as Boston Scientific is already pushing investors on a larger acquisition spree. Earlier this month, it struck a deal to buy Penumbra for about $14.5 billion, paying roughly 73% in cash and 27% in stock. The move aims to broaden its cardiovascular devices lineup.
BSX closed Monday higher by 1.12% at $93.55, but still trailed some rivals despite gains in U.S. stocks. Volume hit roughly 14.5 million shares, surpassing its recent averages, according to MarketWatch data.
Medtech stocks saw a mixed bag on Tuesday. Medtronic edged up roughly 0.6%, while Abbott slipped about 1.4%. The SPDR S&P 500 ETF gained around 0.5%.
Boston Scientific’s acquisition of Nalu is a relatively small add-on, but it digs further into the chronic pain segment—a medtech area known for volatile procedure growth, reimbursement shifts, and fluctuating physician adoption. Investors will be watching closely to see if the business can expand without squeezing margins.
Boston Scientific plans to unveil its fourth-quarter and full-year 2025 earnings on Feb. 4, the company confirmed. CEO Mike Mahoney and CFO Jon Monson will lead a conference call at 8 a.m. ET that day.
Traders are zeroing in on procedure demand within the core heart and vascular franchises, looking closely for any signs that acquisition costs are altering the expense structure. These days, guidance outweighs the actual quarterly results.
The deal pipeline is a double-edged sword. Integration demands pile up quickly, and any misstep—whether slower adoption of pain therapies, rising costs, or extended reviews for pending deals—could darken forecasts and pressure the stock.
Investors are zeroing in on Feb. 4 for management’s 2026 guidance and clues on the timing and execution of the bigger Penumbra deal.
